Assertio Holdings, Inc.

Passed

Class Action Period:
March 29, 2023 - November 08, 2023

Lead Plaintiff Deadline:
March 05, 2024

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.

First Name

Last Name

Phone

Street Address

City

State

Zip

Shares Purchased

Purchase Date

Estimated Loss

The submission of this form does not create an attorney-client relationship.

Allegations

The filed complaint alleges that Assertio Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company’s reliance on Indocin products to boost its net income was unsustainable given the risk of generic competition; (ii) Assertio's acquisition of Spectrum Pharmaceuticals, Inc. and Spectrum’s injection asset, Rolvedon, was less valuable than Assertio had represented to investors; (iii) accordingly, Assertio had overstated the positive impact the sale of Indocin products and the acquisition were likely to have on the Company’s profitability; and (iv) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of Assertio Holdings purchased during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in Assertio Holdings during the relevant time frame, you have until March 05, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.